Regencell Bioscience Holdings Limited (RGC)
USD 61.25
(-20.45%)
USD 61.25
(-20.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -4.73 Million USD | 24.5% |
| 2023 | -6.27 Million USD | 17.64% |
| 2022 | -7.61 Million USD | -451.47% |
| 2021 | -1.38 Million USD | -70.04% |
| 2020 | -812.37 Thousand USD | -107.77% |
| 2019 | -390.99 Thousand USD | -100.14% |
| 2018 | 271.7 Million USD | -21.06% |
| 2017 | 344.2 Million USD | 1.53% |
| 2016 | 339 Million USD | 10.64% |
| 2015 | 306.4 Million USD | 0.0% |
| 2013 | 339.8 Million USD | 1.68% |
| 2012 | 334.2 Million USD | 54.87% |
| 2011 | 215.8 Million USD | -31.14% |
| 2010 | 313.4 Million USD | 10.35% |
| 2009 | 284 Million USD | 0.0% |
| 2007 | 322 Million USD | 4.55% |
| 2006 | 308 Million USD | -4.05% |
| 2005 | 321 Million USD | -15.3% |
| 2004 | 379 Million USD | 0.0% |
| 2002 | 283 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -2.42 Million USD | 0.0% |
| 2024 Q2 | -1155.93 USD | 0.0% |
| 2024 Q1 | -1155.93 USD | 99.96% |
| 2023 FY | -6.27 Million USD | 17.64% |
| 2023 Q1 | -1714.76 USD | 99.96% |
| 2023 Q2 | -3.42 Million USD | -199900.0% |
| 2023 Q4 | -2.84 Million USD | -199899.86% |
| 2023 Q3 | -1422.08 USD | 99.96% |
| 2022 Q3 | -1979.43 USD | 99.95% |
| 2022 Q4 | -3.95 Million USD | -199899.8% |
| 2022 FY | -7.61 Million USD | -451.47% |
| 2022 Q1 | -1829.45 USD | -261.23% |
| 2022 Q2 | -3.65 Million USD | -199900.22% |
| 2021 FY | -1.38 Million USD | -70.04% |
| 2021 Q3 | -506.45 USD | -174.9% |
| 2021 Q4 | -506.45 USD | -0.0% |
| 2021 Q2 | -184.23 USD | 0.0% |
| 2021 Q1 | -184.23 USD | 28.36% |
| 2020 Q2 | -149.01 USD | 0.0% |
| 2020 FY | -812.37 Thousand USD | -107.77% |
| 2020 Q4 | -257.18 USD | 0.0% |
| 2020 Q3 | -257.18 USD | -72.59% |
| 2020 Q1 | -149.01 USD | 0.0% |
| 2019 FY | -390.99 Thousand USD | -100.14% |
| 2018 FY | 271.7 Million USD | -21.06% |
| 2018 Q2 | 98.9 Million USD | 187.5% |
| 2018 Q1 | 34.4 Million USD | -42.86% |
| 2017 Q4 | 60.2 Million USD | -41.1% |
| 2017 Q3 | 102.2 Million USD | 14.57% |
| 2017 Q2 | 89.2 Million USD | -3.04% |
| 2017 Q1 | 92 Million USD | 17.8% |
| 2017 FY | 344.2 Million USD | 1.53% |
| 2016 Q4 | 78.1 Million USD | -8.01% |
| 2016 FY | 339 Million USD | 10.64% |
| 2016 Q3 | 84.9 Million USD | -19.37% |
| 2016 Q2 | 105.3 Million USD | 69.02% |
| 2016 Q1 | 62.3 Million USD | -47.69% |
| 2015 FY | 306.4 Million USD | 0.0% |
| 2015 Q4 | 119.1 Million USD | 127.72% |
| 2015 Q2 | 91.7 Million USD | 56.48% |
| 2015 Q3 | 52.3 Million USD | -42.97% |
| 2015 Q1 | 58.6 Million USD | -31.7% |
| 2014 Q4 | 85.8 Million USD | 22.05% |
| 2014 Q2 | 55.7 Million USD | -49.27% |
| 2014 Q1 | 109.8 Million USD | -6.23% |
| 2014 Q3 | 70.3 Million USD | 26.21% |
| 2013 Q4 | 117.1 Million USD | 104.72% |
| 2013 FY | 339.8 Million USD | 1.68% |
| 2013 Q2 | 82 Million USD | 11.26% |
| 2013 Q1 | 73.7 Million USD | -15.96% |
| 2013 Q3 | 57.2 Million USD | -30.24% |
| 2012 Q4 | 87.7 Million USD | -3.41% |
| 2012 FY | 334.2 Million USD | 54.87% |
| 2012 Q1 | 81.1 Million USD | -19.14% |
| 2012 Q2 | 33.6 Million USD | -58.57% |
| 2012 Q3 | 90.8 Million USD | 170.24% |
| 2011 Q3 | 16.4 Million USD | -62.81% |
| 2011 FY | 215.8 Million USD | -31.14% |
| 2011 Q1 | 54 Million USD | -47.06% |
| 2011 Q2 | 44.1 Million USD | -18.33% |
| 2011 Q4 | 100.3 Million USD | 511.59% |
| 2010 Q1 | 39 Million USD | -59.38% |
| 2010 FY | 313.4 Million USD | 10.35% |
| 2010 Q4 | 102 Million USD | 117.03% |
| 2010 Q3 | 47 Million USD | -49.52% |
| 2010 Q2 | 93.1 Million USD | 138.72% |
| 2009 Q2 | 71 Million USD | -6.58% |
| 2009 Q3 | 62 Million USD | -12.68% |
| 2009 Q1 | 76 Million USD | 16.92% |
| 2009 FY | 284 Million USD | 0.0% |
| 2009 Q4 | 96 Million USD | 54.84% |
| 2008 Q1 | 117 Million USD | 40.96% |
| 2008 Q4 | 65 Million USD | -9.72% |
| 2008 Q3 | 72 Million USD | 26.32% |
| 2008 Q2 | 57 Million USD | -51.28% |
| 2007 FY | 322 Million USD | 4.55% |
| 2007 Q1 | 84 Million USD | -5.62% |
| 2007 Q2 | 85 Million USD | 1.19% |
| 2007 Q3 | 65 Million USD | -23.53% |
| 2007 Q4 | 83 Million USD | 27.69% |
| 2006 Q2 | 90 Million USD | 55.17% |
| 2006 Q3 | 50 Million USD | -44.44% |
| 2006 FY | 308 Million USD | -4.05% |
| 2006 Q4 | 89 Million USD | 78.0% |
| 2006 Q1 | 58 Million USD | -20.77% |
| 2005 Q4 | 73.2 Million USD | 42.97% |
| 2005 FY | 321 Million USD | -15.3% |
| 2005 Q1 | 75.7 Million USD | 45.58% |
| 2005 Q2 | 247 Million USD | 226.29% |
| 2005 Q3 | 51.2 Million USD | -79.27% |
| 2004 Q3 | 61 Million USD | -78.52% |
| 2004 Q1 | 95 Million USD | 352.38% |
| 2004 Q2 | 284 Million USD | 198.95% |
| 2004 Q4 | 52 Million USD | -14.75% |
| 2004 FY | 379 Million USD | 0.0% |
| 2003 Q4 | 21 Million USD | -70.83% |
| 2003 Q2 | 206 Million USD | 167.53% |
| 2003 Q3 | 72 Million USD | -65.05% |
| 2003 Q1 | 77 Million USD | -18.09% |
| 2002 FY | 283 Million USD | 0.0% |
| 2002 Q4 | 94 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 96.955% |
| Theratechnologies Inc. | -10.62 Million USD | 55.427% |
| Safety Shot Inc | -12.18 Million USD | 61.124% |
| Cosmos Health Inc. | -21.83 Million USD | 78.303% |
| Cronos Group Inc. | -81.37 Million USD | 94.179% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 102.266% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 87.902% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 137.818% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -34.308% |
| ProPhase Labs, Inc. | -21.61 Million USD | 78.084% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -0.76% |
| Dynavax Technologies Corporation | -37.02 Million USD | 87.208% |
| Radius Health, Inc. | -3.92 Million USD | -20.681% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -88.323% |
| Alvotech | -354.86 Million USD | 98.665% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1.015% |
| Alpha Teknova, Inc. | -35.56 Million USD | 86.681% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 97.028% |
| SCYNEXIS, Inc. | 72.66 Million USD | 106.518% |
| Harrow Health, Inc. | 580 Thousand USD | 916.677% |
| Biofrontera Inc. | -22.67 Million USD | 79.112% |
| DURECT Corporation | -36.88 Million USD | 87.158% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 10.102% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 110.084% |
| OptiNose, Inc. | -22.74 Million USD | 79.177% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 137.498% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 68.635% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 23.734% |
| SIGA Technologies, Inc. | 83.62 Million USD | 105.665% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 150.763% |
| Shineco, Inc. | -17.06 Million USD | 72.244% |
| Phibro Animal Health Corporation | 53.31 Million USD | 108.884% |
| Procaps Group S.A. | 52.32 Million USD | 109.053% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 44.424% |
| Viatris Inc. | 766.2 Million USD | 100.618% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1.015% |
| Rockwell Medical, Inc. | -6.67 Million USD | 28.985% |
| Incannex Healthcare Limited | -30.04 Million USD | 84.232% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 9.845% |
| Tilray Brands, Inc. | -174.74 Million USD | 97.289% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 102.837% |
| PetIQ, Inc. | 60.01 Million USD | 107.893% |
| Silver Spike Investment Corp. | 7.34 Million USD | 164.532% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 101.888% |
| Journey Medical Corporation | -2.07 Million USD | -128.496% |
| Alimera Sciences, Inc. | -1.47 Million USD | -222.007% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 65.216% |
| Assertio Holdings, Inc. | -243.53 Million USD | 98.055% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 19.613% |
| Embecta Corp. | 221.5 Million USD | 102.138% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 76.375% |
| Procaps Group, S.A. | 38.97 Million USD | 112.154% |
| PainReform Ltd. | -9.58 Million USD | 50.577% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 96.564% |
| Hempacco Co., Inc. | -8.81 Million USD | 46.249% |
| Talphera, Inc. | -16.88 Million USD | 71.954% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 105.403% |
| Alvotech | -354.86 Million USD | 98.665% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.299% |
| Kamada Ltd. | 10.06 Million USD | 147.066% |
| Indivior PLC | -4 Million USD | -18.418% |
| Currenc Group, Inc. | -6.64 Million USD | 28.726% |
| Evoke Pharma, Inc. | -7.43 Million USD | 36.256% |
| Flora Growth Corp. | -50.35 Million USD | 90.593% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 76.375% |
| Evolus, Inc. | -49.23 Million USD | 90.379% |
| HUTCHMED (China) Limited | 18.37 Million USD | 125.778% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 102.405% |
| Akanda Corp. | -10.05 Million USD | 52.875% |